April 19 (Reuters) - GW Pharmaceuticals PLC:
* GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT FOR SEIZURES IN PATIENTS WITH TWO RARE, SEVERE FORMS OF EPILEPSY
* GW PHARMACEUTICALS PLC - EPIDIOLEX WAS GENERALLY WELL TOLERATED WITH MOST ADVERSE EVENTS REPORTED AS MILD OR MODERATE
* GW PHARMACEUTICALS PLC - PDUFA GOAL DATE FOR COMPLETION OF NDA REVIEW OF THE CANNABIDIOL ORAL SOLUTION EPIDIOLEX IS JUNE 27, 2018 Source text for Eikon: Further company coverage: